GB1378348A - Orally administered drug composition for therapy in the treatment of narcotic drug addiction - Google Patents
Orally administered drug composition for therapy in the treatment of narcotic drug addictionInfo
- Publication number
- GB1378348A GB1378348A GB1649072A GB1649072A GB1378348A GB 1378348 A GB1378348 A GB 1378348A GB 1649072 A GB1649072 A GB 1649072A GB 1649072 A GB1649072 A GB 1649072A GB 1378348 A GB1378348 A GB 1378348A
- Authority
- GB
- United Kingdom
- Prior art keywords
- narcotic
- treatment
- drug addiction
- therapy
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 206010013663 drug dependence Diseases 0.000 title abstract 3
- 239000004081 narcotic agent Substances 0.000 title abstract 3
- 208000011117 substance-related disease Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001412 amines Chemical class 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 230000001376 precipitating effect Effects 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 abstract 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 abstract 1
- 239000001263 FEMA 3042 Substances 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 abstract 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract 1
- 239000003513 alkali Substances 0.000 abstract 1
- 230000003113 alkalizing effect Effects 0.000 abstract 1
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 abstract 1
- 229960004193 dextropropoxyphene Drugs 0.000 abstract 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 229960001797 methadone Drugs 0.000 abstract 1
- 239000003887 narcotic antagonist Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000008247 solid mixture Substances 0.000 abstract 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 abstract 1
- 229940033123 tannic acid Drugs 0.000 abstract 1
- 235000015523 tannic acid Nutrition 0.000 abstract 1
- 229920002258 tannic acid Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1378348 Narcotic antagonist WEST LABORATORIES Inc 10 April 1972 [12 April 1971] 16490/72 Heading A5B A preparation useful in combatting narcotic drug addiction consists of a solid composition to be dispersed in an aqueous medium and taken orally, which composition comprises (a) an amine active in the treatment of narcotic drug addiction, the hydrochloride of which is soluble in water but insoluble in alkali, (b) a precipitating agent for the amine selected from (i) alkalizing agents providing an alkaline pH in water either directly or on standing or heating and (2) alkaloids and (c) at least one other solid. The active amine may be propoxyphene or methadone. The precipitating agent may be sodium bicarbonate, disodium hydrogen phosphate or tannic acid.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13334471A | 1971-04-12 | 1971-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1378348A true GB1378348A (en) | 1974-12-27 |
Family
ID=22458150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1649072A Expired GB1378348A (en) | 1971-04-12 | 1972-04-10 | Orally administered drug composition for therapy in the treatment of narcotic drug addiction |
Country Status (4)
| Country | Link |
|---|---|
| CA (1) | CA982478A (en) |
| DE (1) | DE2217132A1 (en) |
| FR (1) | FR2132856B1 (en) |
| GB (1) | GB1378348A (en) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1611880A3 (en) * | 2004-06-30 | 2006-09-13 | Altergon S.A. | Pharmaceutical formulations for the safe administration of drugs used in the treatment of drug addiction |
| WO2011106076A1 (en) | 2010-02-24 | 2011-09-01 | Medical Biological Union Llc | Diversion-and/or abuse-resistant compositions and methods for making the same |
| US8362007B1 (en) | 2010-05-11 | 2013-01-29 | Demerx, Inc. | Substituted noribogaine |
| US8637648B1 (en) | 2010-06-22 | 2014-01-28 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| US8741891B1 (en) | 2010-06-22 | 2014-06-03 | Demerx, Inc. | N-substituted noribogaine prodrugs |
| US8765737B1 (en) | 2010-05-11 | 2014-07-01 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
| US8802832B2 (en) | 2010-06-22 | 2014-08-12 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| US8859764B2 (en) | 2011-01-26 | 2014-10-14 | Demerx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
| US8877921B2 (en) | 2012-01-25 | 2014-11-04 | Demerx, Inc. | Synthetic voacangine |
| US8940728B2 (en) | 2012-12-20 | 2015-01-27 | Demerx, Inc. | Substituted noribogaine |
| US9045481B2 (en) | 2012-12-20 | 2015-06-02 | Demerx, Inc. | Substituted noribogaine |
| US9051343B2 (en) | 2011-12-09 | 2015-06-09 | Demerx, Inc. | Phosphate esters of noribogaine |
| US9150584B2 (en) | 2012-01-25 | 2015-10-06 | Demerx, Inc. | Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them |
| US9358237B2 (en) | 2010-07-23 | 2016-06-07 | Demerx, Inc. | Noribogaine compositions |
| US9394294B2 (en) | 2010-05-11 | 2016-07-19 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
| US9550789B2 (en) | 2014-06-18 | 2017-01-24 | Demerx, Inc. | Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them |
| US9586954B2 (en) | 2010-06-22 | 2017-03-07 | Demerx, Inc. | N-substituted noribogaine prodrugs |
| US9617274B1 (en) | 2011-08-26 | 2017-04-11 | Demerx, Inc. | Synthetic noribogaine |
| US9783535B2 (en) | 2012-12-20 | 2017-10-10 | Demerx, Inc. | Substituted noribogaine |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES8307096A1 (en) * | 1981-06-01 | 1983-07-01 | Orion Yhtymae Oy | Tablets which do not damage the oesophagus. |
| NL8400911A (en) * | 1984-03-22 | 1985-10-16 | Dagra Nv | PROCESS FOR PREPARING A PHARMACEUTICAL FORM OF ADMINISTRATION CONTAINING TETRACYCLINE OR DOXYCYCLINE SALTS. |
| US7220737B1 (en) | 1997-09-04 | 2007-05-22 | Novoneuron, Inc | Noribogaine in the treatment of pain and drug addiction |
| ES2224430T3 (en) | 1997-09-04 | 2005-03-01 | Novoneuron Inc | NORIBOGAINE IN THE TREATMENT OF PAIN AND TOXICOMANIA. |
-
1972
- 1972-04-06 CA CA139,081A patent/CA982478A/en not_active Expired
- 1972-04-10 GB GB1649072A patent/GB1378348A/en not_active Expired
- 1972-04-10 DE DE19722217132 patent/DE2217132A1/en active Pending
- 1972-04-11 FR FR7212647A patent/FR2132856B1/fr not_active Expired
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1611880A3 (en) * | 2004-06-30 | 2006-09-13 | Altergon S.A. | Pharmaceutical formulations for the safe administration of drugs used in the treatment of drug addiction |
| CN102883600B (en) * | 2010-02-24 | 2015-11-25 | 尹温斯博生物技术有限责任公司 | The composition and method of making the same of anti-changed course and/or anti-abuse |
| WO2011106076A1 (en) | 2010-02-24 | 2011-09-01 | Medical Biological Union Llc | Diversion-and/or abuse-resistant compositions and methods for making the same |
| CN102883600A (en) * | 2010-02-24 | 2013-01-16 | 医学生物学联合有限责任公司 | Diversion-and/or abuse-resistant compositions and methods for making the same |
| EP2538779A4 (en) * | 2010-02-24 | 2013-08-21 | Medical Biolog Union Llc | Diversion-and/or abuse-resistant compositions and methods for making the same |
| US8362007B1 (en) | 2010-05-11 | 2013-01-29 | Demerx, Inc. | Substituted noribogaine |
| US9394294B2 (en) | 2010-05-11 | 2016-07-19 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
| US8765737B1 (en) | 2010-05-11 | 2014-07-01 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
| US8741891B1 (en) | 2010-06-22 | 2014-06-03 | Demerx, Inc. | N-substituted noribogaine prodrugs |
| US9586954B2 (en) | 2010-06-22 | 2017-03-07 | Demerx, Inc. | N-substituted noribogaine prodrugs |
| US8637648B1 (en) | 2010-06-22 | 2014-01-28 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| US8802832B2 (en) | 2010-06-22 | 2014-08-12 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| US9308272B2 (en) | 2010-06-22 | 2016-04-12 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| US9358237B2 (en) | 2010-07-23 | 2016-06-07 | Demerx, Inc. | Noribogaine compositions |
| US9403817B2 (en) | 2011-01-26 | 2016-08-02 | Demerx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
| US8859764B2 (en) | 2011-01-26 | 2014-10-14 | Demerx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
| US9617274B1 (en) | 2011-08-26 | 2017-04-11 | Demerx, Inc. | Synthetic noribogaine |
| US9051343B2 (en) | 2011-12-09 | 2015-06-09 | Demerx, Inc. | Phosphate esters of noribogaine |
| US9150584B2 (en) | 2012-01-25 | 2015-10-06 | Demerx, Inc. | Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them |
| US9469649B2 (en) | 2012-01-25 | 2016-10-18 | Demerx, Inc. | Synthetic voacangine |
| US8877921B2 (en) | 2012-01-25 | 2014-11-04 | Demerx, Inc. | Synthetic voacangine |
| US9045481B2 (en) | 2012-12-20 | 2015-06-02 | Demerx, Inc. | Substituted noribogaine |
| US8940728B2 (en) | 2012-12-20 | 2015-01-27 | Demerx, Inc. | Substituted noribogaine |
| US9783535B2 (en) | 2012-12-20 | 2017-10-10 | Demerx, Inc. | Substituted noribogaine |
| US9550789B2 (en) | 2014-06-18 | 2017-01-24 | Demerx, Inc. | Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2132856B1 (en) | 1975-04-25 |
| CA982478A (en) | 1976-01-27 |
| FR2132856A1 (en) | 1972-11-24 |
| DE2217132A1 (en) | 1972-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1378348A (en) | Orally administered drug composition for therapy in the treatment of narcotic drug addiction | |
| IL65875A0 (en) | Capsules containing the active principle of an allergen,and process for their preparation | |
| ES2130278T3 (en) | PREPARATION OF CONTROLLED RELEASE MORPHINE. | |
| ES459938A1 (en) | Pharmaceutical insertion compositions and a process for producing the same | |
| DE3773468D1 (en) | HYDROMORPHONE COMPOSITION WITH CONTROLLED ACTIVE SUBSTANCE RELEASE. | |
| KR840000229A (en) | Method for preparing oral dosage form of dipyridamole | |
| Castell et al. | Nephrogenic diabetes insipidus due to demethylchlortetracycline hydrochloride | |
| ATE43497T1 (en) | PHARMACEUTICAL FORMULATION WITH CONTROLLED ABSORPTION. | |
| GB1395090A (en) | Stabilized hormone compositions | |
| KR930700163A (en) | Methods of treating and / or diagnosing soft tissue tumors | |
| EP0381181A3 (en) | A system for the controlled release of active agents and a process for its preparation | |
| ATE8739T1 (en) | PHARMACEUTICAL PREPARATIONS. | |
| ES451256A1 (en) | Stable preparation of water-soluble salts of dehydroepiandrosterone sulfate for parenteral administration | |
| GB1242547A (en) | Depot medicaments in capsule form | |
| Ivey et al. | Effect of intravenous salicylates on the gastric mucosal barrier in man | |
| NO841372L (en) | PROCEDURE FOR PREPARING DIPYRIDAMOL PREPARATIONS WITH PH-INDEPENDENT REGULATED RELEASE | |
| ES427653A1 (en) | 3-Hydroxyacyl aminomethyl-5-acylamino-2,4,6-triiodobenzoic acid salts as x-ray contrast agents | |
| SU1814764A3 (en) | Method of preparing of agent for purulent-necrotic wound treatment | |
| YU120291A (en) | HERBICIDE PREPARATIONS | |
| GB1254057A (en) | Improvements in or relating to therapeutical composition containing vincamine | |
| GB1420976A (en) | Pharmaceutical compositions for use in the treatment of certain respiratory diseases or conditions in prematurely born children | |
| FR2329260A1 (en) | Licking block for administering curative doses of medicaments - esp. anthelmintics, contains organoleptic agents such as sodium chloride and mineral salts | |
| GB1386927A (en) | Preparations for combatting swine dysentery | |
| GB1284884A (en) | A new insoluble salt of kanamycin | |
| EP0153171A3 (en) | New 2-hydroxyethyl-trimethylammonium salt of 1-ethyl-3-carboxy-4-oxo-6,7-methylenedioxy-1,4-dihydroquinoline, process for the preparation thereof and pharmaceutical composition containing it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed | ||
| PLNP | Patent lapsed through nonpayment of renewal fees |